Health News Releases

  • Today April 23
May 24, 2021 14:30
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dos
May 24, 2021 13:30
CHMP issues positive opinion for Jardiance® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fraction
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with
May 24, 2021 11:50
CNPharm’s Game Changer COVID-19 Drug Introduced in World Class Academic Journal
Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article regarding the research results of CP-COV03, a Niclosamide-based ora
May 24, 2021 10:15
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted a New Drug Applic
May 24, 2021 10:10
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceu
May 21, 2021 11:50
Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced 40 abstracts, including seven oral presentations and seven poster discussions, from
May 20, 2021 16:00
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented d
May 20, 2021 15:00
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal grow
May 18, 2021 11:40
Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab
Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate
May 18, 2021 10:30
New Study Assesses the Effects of Masimo Patient SafetyNet™ on Nursing Workflows in the General Ward
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of PeriAnesthesia Nursing in which Drs. Mashasi Ishikawa and Atsuhiro Sakamoto at Nippon Medical School in Tokyo
Graph 1: CP-COV03’s SARS-CoV2 in-vivo efficacy study results
May 14, 2021 17:30
Hyundai Bioscience: Niclosamide-based CP-COV03, an Oral Antiviral Drug May Be a Problem Solver for COVID-19
Hyundai Bioscience (KOSDAQ 048410) announced that Dr. Jin-Ho Choi, a Chief Scientist of its major shareholding bio-tech company CNPharm and Chair Professor at Dankook University, presented the study t
May 14, 2021 16:30
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostr
May 14, 2021 15:40
Humanigen Reports First Quarter 2021 Financial Results
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
May 14, 2021 09:20
Nuclera Acquires E Ink Digital Microfluidics Unit
Nuclera, a fast-growing biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the leading innovator of electronic ink technology, are pleased to announce the acquisi
May 13, 2021 17:30
Patient Safety Movement Foundation Names Five Individuals to Inaugural Healthcare Safety Fellowship Program
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has selected five individuals for its inaugu
May 13, 2021 16:20
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESIDENT AND CHIEF EXECUTIVE O
May 12, 2021 13:40
MagBio Genomics Inc. Develops Automated RNA Purification Chemistry for Mawi iSWAB-RNA v2 on Thermofisher KingFisher™ Flex
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purifi
May 12, 2021 10:40
Aster DM Healthcare Announces Global Nursing Award Worth US $ 250,000
To recognize the phenomenal contribution of nurses to the healthcare delivery system across the world, Aster DM Healthcare has launched the Aster Guardian Global Nursing Award. This is all the more re
May 11, 2021 14:00
SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting res
May 11, 2021 11:50
Yale-Boehringer Ingelheim Biomedical Data Science Fellowship Program Seeks to Attract Top Researchers from Around the World
Yale University, in partnership with Boehringer Ingelheim, today announced the launch of a Biomedical Data Science Fellowship program designed to attract and support some of the brightest and most inn
May 11, 2021 11:30
Study Investigates the Ability of Masimo O3® to Aid in Monitoring Septic Shock ICU Patients and Predicting Mortality
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Journal of Anesthesia & Clinical Research in which Dr. Debdipta Das and colleagues at Medical College Kolkata in India ev
May 10, 2021 10:00
EAG Expands Medical Device Testing Services with New Laboratory
EAG Laboratories is expanding its medical device testing capabilities with a new 20,000 square-foot laboratory located in St. Louis, Mo. The new laboratory is a bespoke design to support the requir
May 07, 2021 16:20
CrownBio Acquires OcellO B.V. to Expand Its Preclinical In Vitro Drug Development Service Offerings
Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a
May 07, 2021 16:10
Aegis Spine's Attempt to Stay Court Order Halting Sale of Their AccelFix-XT Denied, Life Spine Announces
Life Spine won a second ruling barring Aegis Spine, Inc. from marketing, selling, or distributing devices in its AccelFix-XT product line. A preliminary injunction preventing Aegis’s marketing and
May 07, 2021 16:00
93rd Vifor Pharma Group Annual General Meeting
Regulatory News: At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19 p
25 per page50 per page75 per page100 per page